Non Hodgkin Lymphoma Clinical Trial
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Histologically documented diagnosis of DLBCL.
Phase 1: any DLBCL subtype.
Phase 2: activated B-cell or unclassifiable subtypes confirmed by immunohistochemistry using the Hans algorithm
Relapsed or refractory DLBCL, defined as having received at least 1 but no more than 3 prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant.
Fluorodeoxyglucose-avid disease (based on local evaluation) per the Lugano Classification. Fluorodeoxyglucose-avid disease is defined as disease with a 5-point scale score of 4 or 5.
Archived tumor tissue (block or 15-20 unstained slides) available, or be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy (or, in less accessible lymph nodes, 4 to 8 core biopsies).
At least 1 measurable (≥ 2 cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI).
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Transformed DLBCL or DLBCL with coexistent histologies (eg, follicular or mucosa-associated lymphoid tissue lymphoma).
Primary mediastinal (thymic) large B-cell lymphoma.
Known central nervous system lymphoma (either primary or metastatic).
Allogeneic stem cell transplant within the previous 6 months, or active graft versus host disease following allogeneic transplant.
Use of immunosuppressive therapy within 28 days of starting study treatment. Immunosuppressive therapy includes but is not limited to cyclosporine A, tacrolimus, or high-dose corticosteroids. Subjects receiving corticosteroids must be at a dose level ≤ 10 mg/day within 7 days of initiating study treatment.
Prior or concurrent therapy with a Janus kinase inhibitor or Bruton's tyrosine kinase inhibitor
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 21 Locations for this study
Scottsdale Arizona, 85259, United States
Duarte California, 91010, United States
Long Beach California, 90813, United States
Los Angeles California, 90033, United States
San Diego California, 92093, United States
Miami Beach Florida, 33140, United States
Augusta Georgia, 30912, United States
Baltimore Maryland, 21201, United States
Ann Arbor Michigan, 48109, United States
Lansing Michigan, 48910, United States
Billings Montana, 59102, United States
Las Vegas Nevada, 89169, United States
Little Silver New Jersey, 07739, United States
Buffalo New York, 14263, United States
New York New York, 10065, United States
Toledo Ohio, 43623, United States
Tulsa Oklahoma, 74146, United States
Danville Pennsylvania, 17822, United States
Philadelphia Pennsylvania, 19104, United States
Houston Texas, 77030, United States
Puyallup Washington, 98373, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.